Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19
Authors:
- Antonia ParmeggianiAntonia Parmeggiani
- Annio PosarAnnio Posar
- Simonetta SangiorgiSSSimonetta Sangiorgi
- Paola Giovanardi-RossiPGPaola Giovanardi-Rossi
- 1 January 2004
- journal article
- case report
- Published by Elsevier in Brain and Development
- Vol. 26 (1) , 63-66
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Clinical relevance of genetic polymorphisms in the human CYP2C subfamilyBritish Journal of Clinical Pharmacology, 2001
- Pharmacogenetics and psychopharmacotherapyJournal of Clinical Pharmacy and Therapeutics, 2000
- Effect of Felbamate on Clobazam and Its Metabolite Kinetics in Patients With EpilepsyTherapeutic Drug Monitoring, 1999
- Landau–Kleffner syndrome (LKS): long-term follow-up and links with electrical status epilepticus during sleep (ESES)Brain and Development, 1999
- An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in CaucasiansPharmacogenetics, 1998
- Treatment of electrical status epilepticus by short diazepam (DZP) cycles after DZP rectal bolus testBrain and Development, 1995
- The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.Journal of Biological Chemistry, 1994
- Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsyBrain and Development, 1991